These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9799755)

  • 21. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis.
    Garnero P; Borel O; Delmas PD
    Clin Chem; 2001 Apr; 47(4):694-702. PubMed ID: 11274020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R; Inaba M; Nakatsuka K; Miki T; Naka H; Moriguchi A; Nishizawa Y
    J Bone Miner Metab; 2004; 22(2):127-31. PubMed ID: 14999523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region.
    Fledelius C; Johnsen AH; Cloos PA; Bonde M; Qvist P
    J Biol Chem; 1997 Apr; 272(15):9755-63. PubMed ID: 9092508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency.
    Kamel S; Brazier M; Rogez JC; Vincent O; Maamer M; Desmet G; Sebert JL
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3717-21. PubMed ID: 8855828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices.
    Woitge HW; Pecherstorfer M; Li Y; Keck AV; Horn E; Ziegler R; Seibel MJ
    J Bone Miner Res; 1999 May; 14(5):792-801. PubMed ID: 10320528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
    Taga M; Uemura T; Minaguchi H
    J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoassay for quantifying type I collagen degradation products in urine evaluated.
    Bonde M; Qvist P; Fledelius C; Riis BJ; Christiansen C
    Clin Chem; 1994 Nov; 40(11 Pt 1):2022-5. PubMed ID: 7955372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment.
    Bonde M; Qvist P; Fledelius C; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1995 Mar; 80(3):864-8. PubMed ID: 7883844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary bone resorption markers (deoxypyridinoline and C-terminal telopeptide of type I collagen) in healthy persons, postmenopausal osteoporosis and patients with type I diabetes.
    Fassbender WJ; Gödde M; Brandenburg VM; Usadel KH; Stumpf UC
    Adv Med Sci; 2009; 54(1):1-6. PubMed ID: 19482729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index.
    Mouritzen U; Christgau S; Lehmann HJ; Tankó LB; Christiansen C
    Ann Rheum Dis; 2003 Apr; 62(4):332-6. PubMed ID: 12634232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
    Charni N; Juillet F; Garnero P
    Arthritis Rheum; 2005 Apr; 52(4):1081-90. PubMed ID: 15818703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-sectional evaluation of bone metabolism in men.
    Szulc P; Garnero P; Munoz F; Marchand F; Delmas PD
    J Bone Miner Res; 2001 Sep; 16(9):1642-50. PubMed ID: 11547833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
    Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
    J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
    J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The concentrations of osteocalcin and degradation products of type I collagen in pregnant women with pre-eclampsia.
    Gorzelak M; Darmochwal-Kolarz D; Jablonski M; Rolinski J; Leszczynska-Gorzelak B; Modrzewski K; Oleszczuk J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):23-7. PubMed ID: 11516795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men.
    Fall PM; Kennedy D; Smith JA; Seibel MJ; Raisz LG
    Osteoporos Int; 2000; 11(6):481-5. PubMed ID: 10982162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isoaspartyl bond formation within N-terminal sequences of collagen type I: implications for their use as markers of collagen degradation.
    Brady JD; Ju J; Robins SP
    Clin Sci (Lond); 1999 Feb; 96(2):209-15. PubMed ID: 9918902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine.
    Gertz BJ; Shao P; Hanson DA; Quan H; Harris ST; Genant HK; Chesnut CH; Eyre DR
    J Bone Miner Res; 1994 Feb; 9(2):135-42. PubMed ID: 8140926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.